首页> 外文期刊>EFSA Journal >Frutalose?, a mixture of fructans obtained from enzymatic hydrolysis of chicory inulin, and normal defecation: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006
【24h】

Frutalose?, a mixture of fructans obtained from enzymatic hydrolysis of chicory inulin, and normal defecation: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006

机译:Frutalose?,从菊苣菊蛋白的酶促水解中获得的玻璃叶蛋白和正常排便的混合物:根据第13(5)条第13(5)条第1924/2006条的第13(5)条评估健康索赔

获取原文
           

摘要

Following an application from Sensus B.V. (Royal Cosun), submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of the Netherlands, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Frutalose? and maintenance of normal defecation. The scope of the application was proposed to fall under a health claim based on newly developed scientific evidence. The Panel considers that Frutalose?, a mixture of fructans obtained from enzymatic hydrolysis of chicory inulin, is sufficiently characterised. The claimed effect proposed by the applicant is ‘contributes to regular bowel function by increasing stool frequency’. The proposed target population is ‘the general healthy adult population’. Maintenance of normal defecation is a beneficial physiological effect provided that it does not result in diarrhoea. One human intervention study showed an effect of Frutalose? on the maintenance of normal defecation by increasing stool frequency and improving stool consistency (softer stools) when consumed daily at a dose of 15 g for 8 weeks. The results have not been replicated in other studies. There is a plausible mechanism by which Frutalose? could exert the claimed effect. The Panel concludes that the evidence provided is insufficient to establish a cause and effect relationship between the consumption of Frutalose? and maintenance of normal defecation under the proposed conditions of use.
机译:根据Sensus BV(Royal Cosun)的申请,根据“荷兰省饮食产品”EFSA小组(EC)第13(ec)第13(ec)第13(EC)第13(EC)第13(EC)第13(EC)授权授权。营养产品的EFSA小组,营养和过敏症(NDA)被要求向科学证实提供与弗卢特罗索相关的健康索赔的意见?和维持正常排便。申请的范围是根据新制定的科学证据的健康索赔下降。面板认为Frutalose?,足够的菊苣菊蛋白的酶水解中获得的玻璃体蛋白的混合物。申请人提出的要求保护的效果是“通过增加粪便频率的定期肠功能。拟议的目标人口是“一般健康的成年人口”。常规排便的维持是一种有益的生理效果,条件是它不会导致腹泻。一种人类干预研究表明弗劳斯索斯的影响?在每天在15克的剂量消耗8周时通过增加粪便频率和改善粪便一致性(更柔软的粪便)的正常排便。结果尚未复制其他研究。 Frutalose有一种合理的机制吗?可以发挥声称的效果。小组得出结论,提供的证据不足以建立弗卢提索消费之间的成因和效果关系?并在拟议的使用条件下维护正常排便。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号